ASH 2014: Phase II SAL-Soraml trial shows that sorafenib versus placebo in addition to standard therapy improves event-free survival and relapse-free survival rate in younger patients wit…

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Christoph Röllig (Universitätsklinikum Dresden, Dresden, Germany) discusses the phase II Study Alliance Leukemia (SAL)-Soraml trial, which evaluated sorafenib versus placebo in addition to standard therapy in younger patients (1860 years old) with newly diagnosed acute myeloid leukaemia.